Daré Bioscience (DARE) Corporate presentation summary

Investment highlights and market opportunity

• Focused exclusively on women's health, targeting large, underserved markets including sexual health, menopause, contraception, and HPV-related conditions.

• Revenue generation begins in 2026 with the launch of Flora Sync LF5 and DARE to PLAY, aiming for profitability as sales scale.

• Over $75 million in non-dilutive funding awarded since 2018 from Gates Foundation, ARPA-H, and NIH, supporting development and validating the approach.

• Women's health represents a significant market, with 40 million U.S. women experiencing sexual dysfunction, 51 million with menopausal symptoms, and 43 million using contraception.

Product pipeline and clinical development

• Robust pipeline addresses women's health across all life stages, including products for vaginal microbiome, sexual arousal, contraception, menopause, HPV, and pregnancy support.

• Flora Sync LF5, a non-hormonal probiotic vaginal capsule, launched June 2026, demonstrated 96% efficacy in restoring microbiome balance within 3 days.

• DARE to PLAY (Sildenafil Cream) targets female sexual arousal disorder, with prescriptions dispensing summer 2026 and positive Phase 2b results.

• Ovaprene, a hormone-free monthly contraceptive, is in Phase 3 with topline data expected in 2027; pivotal study ongoing with interim results aligning with expectations.

• DARE-HPV, an investigational antiviral for persistent high-risk HPV, began Phase 2 in May 2026 and received $10M in funding.

Commercial strategy and infrastructure

• Integrated commercial platform includes DARE Health Hub, telehealth access, and direct patient engagement for scalable growth.

• Strong clinical relationships with OBGYNs and women's health specialists to accelerate adoption and expand provider engagement.

• Commercial launch of Flora Sync LF5 and DARE to PLAY in 2026 marks transition to a revenue-generating company.

• XACIATO, an FDA-approved product for bacterial vaginosis, is commercialized via partnership with Organon, with potential milestone payments up to $180 million.